Cytyc Corporation Chairman and CEO Scheduled to Present at Piper Jaffray Health Care Conference.

MARLBOROUGH, Mass. -- Cytyc Corporation (Nasdaq: CYTC) today announced that Patrick J. Sullivan, chairman, president, and chief executive officer, is scheduled to present at Piper Jaffray Health Care Conference, on November 30, at 9:00 a.m., Eastern, at The Pierre Hotel in New York City.

A live webcast and recording of the presentation will be available on Cytyc's website, http://ir.cytyc.com. The replay will be available approximately 24 hours after the presentation until December 15.

Cytyc Corporation is a leading provider of best-in-class medical technology that enables physicians and laboratories to improve patients' lives throughout the world. Cytyc provides diagnostic and minimally invasive surgical products targeting cancer and women's health. The ThinPrep([R]) System is the most widely used method for cervical cancer screening in the United States. The ThinPrep System consists of the ThinPrep([R]) 2000 Processor, ThinPrep([R])3000 Processor, ThinPrep([R]) Imaging System, and related reagents, filters, and other supplies. The ThinPrep System also provides the platform from which the Company launched its expansion into breast cancer risk assessment with the FirstCyte([R]) Breast Test. The NovaSure([R]) Impedance Controlled Endometrial Ablation System, or the NovaSure([R]) System, is an innovative endometrial ablation device to treat menorrhagia, or excessive menstrual bleeding. The MammoSite([R]) Radiation Therapy System is a single-use device for the treatment of breast cancer that positions radiation sources directly into the post-lumpectomy site to optimize radiation treatment delivery while minimizing damage to healthy tissue. The GliaSite([R]) Radiation Therapy System is for the treatment of malignant brain tumors.

Cytyc is traded on The Nasdaq Stock Market under the symbol CYTC. Cytyc, ThinPrep, FirstCyte, NovaSure, MammoSite, and GliaSite are registered trademarks of Cytyc Corporation.